The AHCA Quality Initiative goal to reduce antipsychotics use is in sight, the group announced Wednesday. The goal is 15% by the end of this month. The group used federal data in its calculations.
Like many bad habits, the overuse of antipsychotics is not going down without a fight. Still, there are reasons for long-term optimism.
I'm an administrator who's read all of this stuff about overuse of antipsychotics on long-term care residents. I like and trust my director of nursing, medical director and clinical staff — to a degree, that is — but what can I do to REALLY know that we're not overusing this stuff, and would not be liable for some sort of adverse regulatory or court findings?
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes. The agreement also will settle kickback charges related to the nation's largest long-term care pharmacy, Omnicare.
Nursing home staff should adopt evidence-based approaches to pressure ulcer prevention and treatment, and significantly more research is needed, a top expert said Saturday.
Two big reactions hit me when news of Johnson & Johnson's $2.2 billion Risperdal settlement with the government landed this week. First, J&J probably made a lot more than it's paying out and, second, some individual probably is going to cash a nice paycheck for bringing it all to light.
The leader of the nation's largest nursing home association trumpeted gains made over the last three years but also exhorted members to press for more change.
Leonard Russ will lead the American Health Care Association's Board of Governors as its new chairman, the organization has announced. The nation's largest long-term care provider association concluded its annual convention and expo yesterday.
Nursing homes have made strides toward reducing antipsychotic medication use among residents with dementia, according to new figures from the Centers for Medicare & Medicaid Services and the American Health Care Association/National Center for Assisted Living.
A government investigation into nursing homes' antipsychotic prescribing practices will not move forward due to budget and staff cuts, according to nonprofit investigative news organization The Center for Public Integrity.
Providers and other stakeholders are invited to a national conference call on improving dementia care by lessening the use of antipsychotic medications in nursing homes. The call begins at 12:30 p.m. Eastern on July 10 and is sponsored by The Centers for Medicare & Medicaid Services. The regulatory agency has created a "national partnership" that promotes person-centered, comprehensive, interdisciplinary care.
The Centers for Medicare & Medicaid Services has updated survey guidelines regarding nursing homes' use of antipsychotic medications for dementia care. The 59-page interim guidance revises Appendix P and Appendix PP of the State Operations Manual.
Long-term care pharmacy Omnicare will not face charges that it engaged in "nationwide" Medicare fraud for off-label antipsychotics prescriptions, a federal judge recently ruled. However, the pharmacy still faces more limited False Claims Act charges over billing for antipsychotic drugs allegedly used for dementia care.
The top professional association of long-term care physicians and medical directors has reiterated its commitment to reducing the use of antipsychotics for dementia care. It did so Tuesday, in response to a recent report that criticized prescribing practices.
Long-term care organizations have responded to a report that physicians are prescribing antipsychotic medications for seniors without proper oversight from the Centers for Medicare & Medicaid Services. This is hampering efforts to reduce off-label antipsychotic use for dementia care in nursing homes, according to ProPublica, which compiled the report based on a review of Medicare Part D claims.
Skilled nursing providers fell well short of reaching a 15% reduction in off-label antipsychotic use by the end of 2012, the American Health Care Association announced Monday.
Providers should be taking most of their dementia residents off antipsychotics — and can generally do so without fear of relapse to dementia-related behaviors — researchers say.
Skilled nursing facilities are expected to have missed their overall goal of reducing off-label use of antipsychotics by 15% for 2012, but they should continue to push for reductions, provider leaders said.
Reducing the number of residents with dementia who are on antipsychotics starts with reassessment, experts advised at this week's American College of Health Care Administrators convocation In Orlando. The key is a multi-step process providers can follow.
A majority of long-term care providers reduced hospital readmissions and the off-label use of antipsychotics within the last year, according to the American Health Care Association. The organization recently posted a progress report on the AHCA Quality Initiative, which was launched in February 2012.
It's noteworthy that the Taylor Care Center in Jacksonville, FL, recently marked the 100th birthday of two residents by inviting an Elvis impersonator to perform. More remarkable: The event celebrated 42 residents who are at least 90.
Nursing homes using antipsychotic drugs for dementia care can and should take most residents off these medications, according to recently published research.
Skilled nursing facilities are making progress in reducing the off-label use of antipsychotics but are expected to fall far short of an overall 15% reduction goal.
While antipsychotic measurements can vary, providers must carefully and thoroughly examine all antipsychotic medication use in their facility.
The landmark legislation known as "OBRA '87" (the Omnibus Budget Reconciliation Act of 1987) significantly limited the inappropriate use of antipsychotic drug use in long-term care facilities. Indeed, among OBRA '87's goals was the elimination of chemical restraints, typically associated with antipsychotic drugs. A quarter of a century after the passage of OBRA '87, the Centers for Medicare & Medicaid Services (CMS) and numerous professional organizations are redoubling their efforts to further reduce the use of antipsychotic drugs in long term care.
Federal performance measures for nursing homes should reflect the quality of care provided in these facilities and should not be driven only by the goal of aligning performance measures among different care settings, according to a recent report from the National Quality Forum.
Providers are invited to take part in a 90-minute teleconference Thursday that is aimed at improving dementia care in nursing homes. The mission of the National Partnership to Improve Dementia Care will be the focus of the call, which starts at 1:30 p.m. Eastern Time. The Centers for Medicare & Medicaid Services says it hopes the partnership's work will lead to less use of antipsychotic medications. CMS experts will discuss goals, quality measures and ongoing efforts before ending with a question-and-answer session. Eligible professionals may earn continuing education credits.
The former director of nursing at a California nursing home was sentenced Wednesday to three years in prison for administering powerful drugs to subdue residents.
Adding to the concerns about off-label use of antipsychotics, a new study has found four of the most common medications lack safety and effectiveness in older adults.
Providers still have two months left to achieve a reduction of 15% in off-label use of antipsychotics, a goal that is achievable, a top medical expert says.